Actinogen Medical targets Alzheimer’s treatment gap in projected $20BN market
Kort samengevat
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) is approaching a defining clinical milestone as it advances Xanamem, a once-daily oral therapy designed to slow Alzheimer’s disease by controlling elevated cortisol in the brain.
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij Proactiveinvestors UK.
Lees het volledige bericht ↗